{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:50:59Z","timestamp":1740153059413,"version":"3.37.3"},"reference-count":18,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To characterize skin severity and joint activity outcomes and associated treatment changes in patients with psoriatic arthritis (PsA) through 12 months of follow-up after enrollment in the Corrona Psoriatic Arthritis\/Spondyloarthritis (PsA\/SpA) Registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients \u2265 18 years of age with a diagnosis of PsA and a history of psoriasis between March 21, 2013, and September 30, 2016, were enrolled (n = 647). Demographics, clinical features, and treatment characteristics were collected and stratified by skin severity and joint activity. Change in joint and skin from enrollment to the 12-month visit was classified by change in category of Clinical Disease Activity Index (CDAI) or body surface area (BSA). Tests of association evaluated the relationship between changes in therapy and changes in skin severity and joint activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Patients with improvement in both joint activity and skin severity saw the largest median reduction in both CDAI and BSA, while those who worsened in both had the greatest median increase in both CDAI and BSA. The majority of PsA patients (&gt; 50%) had no change in skin severity regardless if they had reduced therapy (50%), no therapy changes (54%), or increased therapy (56%;<jats:italic>P<\/jats:italic>= 0.5875). However, there was a significant association between changes in therapy and changes in joint activity (<jats:italic>P<\/jats:italic>&lt; 0.001). Patients who increased therapy were more likely to have improvement in joint activity (32%) compared to patients who reduced therapy (22%) or had no therapy changes (11%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The clinical implication for our findings suggests the assessment and incorporation of both skin and joint components may be advisable.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.190422","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T16:19:36Z","timestamp":1588349976000},"page":"376-384","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA\/SpA Registry"],"prefix":"10.3899","volume":"48","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol J.","family":"Etzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Huster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia M.","family":"Muram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon","family":"Dodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2769-3188","authenticated-orcid":false,"given":"Mwangi J.","family":"Murage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William N.","family":"Malatestinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.1","DOI":"10.1016\/j.jaad.2013.07.023"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.2","DOI":"10.1016\/j.jaad.2013.11.013"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.3","DOI":"10.1016\/j.jaad.2008.02.040"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.4","DOI":"10.1093\/rheumatology\/ker365"},{"key":"2022070101451360000_48.3.376.5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/annrheumdis-2015-eular.1506","article-title":"SAT0578 Value of treating both skin and joint manifestations of psoriatic arthritis: post-hoc analysis of the ADEPT Clinical Trial","volume":"74","author":"Mease","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022070101451360000_48.3.376.6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022070101451360000_48.3.376.7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"2022070101451360000_48.3.376.8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol Int"},{"key":"2022070101451360000_48.3.376.9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jdv.14741","article-title":"Consensus on the management of patients with psoriatic arthritis in a dermatology setting","volume":"32","author":"Gisondi","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022070101451360000_48.3.376.10","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/S0140-6736(15)00348-7","article-title":"Is it time for treat to target in psoriatic arthritis?","volume":"386","author":"Gladman","year":"2015","journal-title":"Lancet"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.11","DOI":"10.1016\/S0140-6736(15)00347-5"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.12","DOI":"10.3899\/jrheum.170148"},{"key":"2022070101451360000_48.3.376.13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrrheum.2011.125","article-title":"Management of psoriatic arthritis from the view of the dermatologist","volume":"7","author":"Chang","year":"2011","journal-title":"Nat Rev Rheumatol"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.14","DOI":"10.1136\/ard.2004.032482"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.15","DOI":"10.1080\/09546630600823369"},{"key":"2022070101451360000_48.3.376.16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.sder.2005.01.006","article-title":"Psoriatic arthritis and psoriasis: need for a multidisciplinary approach","volume":"24","author":"Qureshi","year":"2005","journal-title":"Semin Cutan Med Surg"},{"doi-asserted-by":"publisher","key":"2022070101451360000_48.3.376.17","DOI":"10.1016\/j.jaad.2015.05.001"},{"key":"2022070101451360000_48.3.376.18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-018-1601-4","article-title":"Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study","volume":"20","author":"Husni","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T14:55:02Z","timestamp":1696085702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.3899\/jrheum.190422"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190422","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}